Tulane University Health Sciences Center, 1430 Tulane Avenue, SL-42, New Orleans, LA 70112, USA.
Expert Rev Med Devices. 2013 May;10(3):353-66. doi: 10.1586/erd.12.92.
Since their introduction 60 years ago, penile prostheses have remained the standard therapy for the management of refractory erectile dysfunction, with multiple long-term series reporting outcomes. A PubMed search was performed from 1990 to present, and outcomes of penile prosthetics were reviewed. Studies with <12 months follow-up were excluded. Overall mechanical survival of three-piece prostheses range from 81-94, 68-89 and 57-76% at 5, 10 and 15 years, respectively. Contemporary infection rates following recent device modifications are 1-2% (low risk) to 2-3% (high risk). Patient satisfaction ranges from 75-100% and varies by prosthetic device. Outcomes are further reviewed among specialized populations (revision surgery, Peyronie's disease, priapism, corporal fibrosis and neurologic impairments). Penile prostheses remain a viable surgical treatment option with excellent mechanical reliability, low infection rates and significant patient/partner satisfaction.
自 60 年前问世以来，阴茎假体一直是治疗难治性勃起功能障碍的标准疗法，多项长期系列研究报告了其结果。从 1990 年至今，对阴茎假体的结果进行了回顾。排除了随访时间<12 个月的研究。三种假体的总体机械存活率分别为：5 年时为 81-94%、10 年时为 68-89%和 15 年时为 57-76%。在最近的器械改良后，感染率为 1-2%（低风险）至 2-3%（高风险）。患者满意度为 75-100%，因假体类型而异。在特定人群（翻修手术、佩罗尼病、阴茎异常勃起、海绵体纤维化和神经损伤）中也对假体结果进行了进一步评估。阴茎假体仍然是一种可行的手术治疗选择，具有极好的机械可靠性、低感染率和显著的患者/伴侣满意度。
